🔎 Trials Near Me

Hjem › Myelogen leukemi i kronisk fase › New York

Kliniske studier for Myelogen leukemi i kronisk fase i New York

5 studier for Myelogen leukemi i kronisk fase søker deltakere på steder i New York.

Byer i New York

Offisiell studietekst (engelsk)

Study of Olverembatinib (HQP1351) in Patients With CML-CP

  • Ascentage Investigative Site #1068, Rochester
  • Ascentage Investigative Site #1053, Shirley
  • Ascentage Investigative Site #1160, Stony Brook
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 15. sep. 2026 · NCT06423911

Protocol Number: HJKC3-0003. Treatment Free Remission After Asciminib Based Therapy in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed After a Prior Attempt at TKI Discontinuation

  • Roswell Park Comprehensive Cancer Center, Buffalo
  • Memorial Sloan Kettering Cancer Center, New York
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 25. aug. 2026 · NCT04838041

A Real-world Chronic Myelogenous Leukemia (CML) Patient Disease Registry to Describe Patient Experience and Clinical Outcomes Among Patients With CML Receiving Approved First or Second Line Tyrosine Kinase Inhibitor (TKI) Therapy

  • NY Cancer and Blood Specialists, East Setauket
  • SUNY Upstate Medical University, Syracuse
RekruttererObservasjonsstudie
Alder 18 til 100 · Alle kjønn · Oppdatert 20. jul. 2026 · NCT07091019

A Phase 1a/1b Study of ELVN-001 for the Treatment Chronic Myeloid Leukemia

  • Memorial Sloan Kettering Cancer Center, New York
  • Montefiore Medical Center, The Bronx
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 1. apr. 2026 · NCT05304377

A Phase 1/2 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TERN-701 in Participants With Chronic Myeloid Leukemia (CARDINAL)

  • Memorial Sloan Kettering Cancer Center - Main Campus, New York
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 12. jan. 2026 · NCT06163430

Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.